New Zealand markets closed

Avenue Therapeutics, Inc. (ATXI)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.1250-0.0105 (-7.75%)
At close: 04:00PM EDT
0.1255 +0.00 (+0.40%)
After hours: 06:55PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 5.53M
Enterprise value 3.75M
Trailing P/E N/A
Forward P/E 17.99
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.50
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.37

Trading information

Stock price history

Beta (5Y monthly) -0.26
52-week change 3-88.43%
S&P500 52-week change 321.83%
52-week high 31.2800
52-week low 30.1130
50-day moving average 30.1513
200-day moving average 30.4629

Share statistics

Avg vol (3-month) 31.65M
Avg vol (10-day) 3845.52k
Shares outstanding 544.26M
Implied shares outstanding 648.01M
Float 839.44M
% held by insiders 110.88%
% held by institutions 12.80%
Shares short (28 Mar 2024) 4283.13k
Short ratio (28 Mar 2024) 40.15
Short % of float (28 Mar 2024) 40.65%
Short % of shares outstanding (28 Mar 2024) 40.64%
Shares short (prior month 29 Feb 2024) 4163.46k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 323 Sept 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-209.03%
Return on equity (ttm)-535.10%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-10.38M
Diluted EPS (ttm)-0.9800
Quarterly earnings growth (yoy)11.30%

Balance sheet

Total cash (mrq)1.78M
Total cash per share (mrq)0.04
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)1.55
Book value per share (mrq)0.06

Cash flow statement

Operating cash flow (ttm)-9.45M
Levered free cash flow (ttm)-13.49M